Skip to content

Pneumococcal Vaccination of Otitis-prone Children

Conjugate Pneumococcal Vaccination - a Randomized Study in Young Otitis-prone Children

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01263210
Enrollment
109
Registered
2010-12-20
Start date
2003-03-31
Completion date
2010-06-30
Last updated
2010-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Acute Otitis Media

Keywords

Recurrent acute otitis media, Conjugate pneumococcal vaccine, Ventilation tube treatment, Nasopharyngeal flora

Brief summary

Acute otitis media (AOM) is a common childhood disease, which becomes recurrent in 15-20% of the cases. Streptococcus pneumoniae is one of the leading causative agents, and a small reduction in the number of AOM episodes has been noted in unselected child cohorts after vaccination with conjugate heptavalent pneumococcal vaccine. This study was performed in order to investigate whether vaccination could reduce the number of AOM episodes in very young, otitis-prone children.

Detailed description

Ninetysix children (46 vaccinated, 50 not) with an onset of AOM before six months of age, implying a high risk for developing rAOM, were recruited between 2003 and 2007. They were closely followed with clinical visits and nasopharyngeal cultures until the age of two years.

Interventions

BIOLOGICALPrevenar

Sponsors

Financial support was provided by the Swedish Association of Local Authorities and Regions. The vaccine was kindly supplied by Wyeth Lederle.
CollaboratorUNKNOWN
Lund University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
No minimum to 6 Months
Healthy volunteers
No

Inclusion criteria

First episode of acute otitis media before 6 months of age and verified by an otorhinolaryngologist. \-

Exclusion criteria

Allergy to the vaccine, anatomical abnormality (eg cleft palate), chromosomal abnormality, immune deficiency, prematurity, prior administration of gammaglobulin or pneumococcal vaccine and a history of idiopathic thrombocytopenic purpura. \-

Design outcomes

Primary

MeasureTime frameDescription
Possible reduction of the number of acute otitis media episodes after conjugate pneumococcal vaccination in young otitis-prone children2 yearsChildren with an acute otitis media onset before 6 months of age, implying an 80% risk for developing recurrent acute otitis media, were allocated to vaccination with heptavalent conjugate pneumococcal vaccine or to no vaccination. The number of acute otitis media episodes before two years of age in each group were recorded.

Secondary

MeasureTime frameDescription
Nasopharyngeal carriage in young otitis-prone children3 yearsThe children in the vaccination study described above, had nasopharyngeal samples taken very frequently (every other month during the first year in the study, and at every suspected new episode of acute otitis media). The cultures were analyzed and compared with respect to vaccination status, risk factors, proneness to acute otitis media etc

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026